

# N

\*click [HERE](#) for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 [Link to Formulary](#)

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Naldemedine 200 micrograms film-coated tablets (Rizmoic®) SMC 2242	For the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative. Naldemedine compared to placebo significantly improved the spontaneous bowel movement response rate in patients with opioid induced constipation and either non-cancer or cancer pain	Available in line with local guidance for prescribing	<a href="#">180</a>	Sept 2020
Nalmefene 18mg film-coated tablets (Selincro®) (917/13)	The reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL).	Formulary  GPs should signpost patients to appropriate services offering psychosocial support such as:  <a href="#">Tayside Council on Alcohol (TCA)</a>  <a href="#">Addaction (Dundee)</a>  <a href="#">Dundee Drug, Alcohol &amp; Blood Borne Virus (BBV) team</a>  <a href="#">Perth &amp; Kinross Alcohol &amp; Drug Team</a>  <a href="#">Angus Alcohol &amp; Drug Partnership</a>	<a href="#">132</a> <a href="#">131</a>  <a href="#">147</a>	Nov/Dec 2013 Oct /Nov 2013 Apr/May 2015

		<a href="#">(ADP)</a>		
Naloxegol 12.mg and 25mg film-coated tablets (Moventig®) SMC No. 1106/15	Treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).	Formulary  Amber - can be prescribed by General Practice under direction of a specialist.	<a href="#">153</a>	Jan/Feb 2016
Naltrexone hydrochloride/bupropion hydrochloride 8mg/90mg prolonged-release tablets (Mysimba®) SMC2086	As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of • ≥ 30 kg/m <sup>2</sup> (obese), or • ≥ 27 kg/m <sup>2</sup> to < 30 kg/m <sup>2</sup> (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).	Not routinely available as not recommended for use in NHS Scotland	<a href="#">169</a>	July 2018
Naproxen (Stirlescent®) 1154/16	As an add-on treatment for severe refractory eosinophilic asthma in adult patients. Restriction: patients who have had eosinophils of at least 150 cells per microlitre (0.15 x 10 <sup>9</sup> /L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines (Link to Formulary)	<a href="#">156</a>	Sep 2016
Naproxen/esomeprazole (Vimovo®) (734/11)	Symtomatic treatment of OA, RA and AS	Not recommended	<a href="#">112</a>	Dec 2011
Natalizumab (Tysabri®) (979/14)  Superseded by 329/06, see below	Single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) for adult patients aged 18 years and over with high disease activity despite treatment with glatiramer acetate .	Not recommended	<a href="#">139</a>	June/July 2014
Natalizumab (Tysabri®)	Single disease modifying therapy in highly active relapsing	<a href="#">Available in line with local guidance</a>	<a href="#">76 Protocol</a>	Jan 2008

329/06	remitting multiple sclerosis (RRMS) only in patients with rapidly evolving severe RRMS defined by two or more disabling relapses in one year and with one or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.	<a href="#">for prescribing</a>	<a href="#">72</a> <a href="#">64</a>	Sept 2007 2006
Necitumumab 800mg concentrate for solution for infusion (Portrazza®)	In combination with gemcitabine and cisplatin chemotherapy for the treatment of adult patients with locally advanced metastatic epidermal growth factor receptor (AGFR) expressing squamous non small cell lung cancer who have not received prior chemotherapy for this condition	Not available as not recommended for use in NHS Scotland	<a href="#">156</a>	Sep 2016
Nebivolol (Nebilet®) (214/05)	Heart failure in patients over 70 years	Non-formulary	<a href="#">72</a> <a href="#">61</a>	Sept 2007 2006
Nelarabine (Atriance®)	T-ALL and T-LBL		<a href="#">79</a> <a href="#">78</a>	May 2008 Apr 2008
Nepafenac 3mg/mL eye drops, suspension (Nevanac®) (1228/17)	Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.	Available in line with national guidance Hospital Use Only	<a href="#">161</a>	Jun 2017
Nepafenac (Nevanac®) (813/12)	Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.	HOSPITAL ONLY (Ophthalmology clinic)  Restricted to diabetic patients with diabetic retinopathy undergoing cataract surgery.	<a href="#">122</a>	Dec 2012
Nepafenac (Nevanac®) (588/09)	Prevention and treatment of postoperative pain and inflammation associated with cataract surgery	Not recommended	<a href="#">93</a>	Oct/Nov 2009
Neratinib 40mg film-coated tablets (Nerlynx®) SMC 2251	For the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than	Available in line with local guidance for prescribing	<a href="#">180</a>	Sept 2020

	one year ago.			
Netupitant/palensetron 300mg/0.5mg, hard capsule (Akynzeo®) SMC No. 1109/15	In adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy. SMC Restriction: prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy.	Available in line with national guidance	<a href="#">153</a> <a href="#">157</a>	Jan/Feb 2016 Nov 2016
Nevirapine (Viramune prolonged release tablets®) (760/12)	HIV-1	HOSPITAL ONLY (HIV Clinic)	<a href="#">115</a>	Mar/Apr 2012
Nicotinic acid MR (Niaspan®)	Dyslipidaemia	Not recommended	<a href="#">55</a> <a href="#">48</a> <a href="#">38</a>	2006 2005 2004
Nicotinic acid/laropiprant (Tredaptive®)	Dyslipidaemia		<a href="#">96</a>	Apr/May 2010
Nilotinib 150mg and 200mg hard capsules (Tasigna®) SMC No 1325/18	Paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.  Paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib.	Not available as not recommended in NHS Scotland	<a href="#">168</a>	May 2018
Nilotinib (Tasigna®) (709/11)	Newly diagnosed Philadelphia positive chronic myelogenous leukaemia (CML)	Non-formulary - pending protocol update	<a href="#">116</a> <a href="#">109</a>	Apr/May 2012 Sept 2011
Nilotinib (Tasigna®) (440/08)	Chronic phase of Philadelphia positive chronic myelogenous leukaemia (CML)	HOSPITAL ONLY (Haematology)	<a href="#">108</a> <a href="#">Protocol</a> <a href="#">80</a>	Aug 2011 June 2008
Nintedanib 100mg and 150mg soft capsules	In adults for the treatment of chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype other	Not routinely available as local clinical experts do not wish to add	<a href="#">185</a>	July 2021

(Ofev®) SMC2331	than idiopathic pulmonary fibrosis (IPF).	the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Nintedanib (Ofev®) (1076/15)	For use in adults for the treatment of idiopathic pulmonary fibrosis (IPF).	Non-formulary - pending protocol review	<a href="#">152</a>	Nov/Dec 2015
Nintedanib (Vargatef®) (1027/15)	For the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy	Available in line with national guidance	<a href="#">147</a> <a href="#">157</a>	Apr 2015 Nov 2016
Niraparib (Zejula) SMC2338	As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III or IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. In a randomised, double-blind, phase III study, niraparib significantly improved progression-free survival compared with placebo.	Available in line with national guidance	<a href="#">185</a>	July 2021
Nintedanib soft capsules (Ofev®) SMC2513	In adults for the treatment of idiopathic pulmonary fibrosis (IPF).	Available in line with national guidance	193	
Niraparib tosylate monohydrate 100mg hard capsules (Zejula®) SMC No 1341/18	As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.  SMC restriction: to patients who do not have a germline BRCA mutation.  Niraparib was assessed in a double blind, randomised, placebo controlled phase III study of patients with high grade serous, recurrent, platinum-sensitive ovarian,	Available in line with national guidance	<a href="#">170</a>	Sep 2018

	fallopian tube or primary peritoneal cancer in which there had been an objective response to the most recent platinum-based chemotherapy regimen. Niraparib maintenance was associated with a significantly improved progression free survival when compared with placebo.			
Nitisinone 2mg, 5mg, 10mg and 20mg hard capsules and 4mg/ml oral suspension (Orfadin®) SMC2450	Treatment of adult patients with alkaptonuria (AKU).	Not available as not recommended for use in NHS Scotland	<a href="#">188</a>	April 2022
Nivolumab solution for infusion (Opdivo®) SMC2620	in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma with tumour cell programmed death ligand (PD-L1) expression $\geq 1\%$	Not available as not recommended for use in NHS Scotland	<a href="#">195</a>	December 2023
Nivolumab concentrate for solution for infusion (Opdivo) SMC2619	in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumours $\geq 4$ cm or node positive) non-small cell lung cancer in adults.	Available in line with national guidance	196- awaiting publication	Feb 2024
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2503	As monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression $\geq 1\%$ , who are at high risk of recurrence after undergoing radical resection of MIUC. In a double-blind, randomised, phase III study, disease-free survival was significantly improved with adjuvant nivolumab compared with placebo in patients with MIUC at high risk of recurrence after surgery.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">192</a>	April 2023
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2458	In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a	Available in line with national guidance	<a href="#">191</a>	Nov 2022

	<p>combined positive score (CPS) <math>\geq 5</math>.</p> <p>In a phase III study, nivolumab in combination with chemotherapy was associated with significantly improved progression-free survival and overall survival compared with chemotherapy alone.</p>			
<p>Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2429</p>	<p>As monotherapy for the adjuvant treatment of adult patients with completely resected oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.</p> <p>In one randomised, double-blind, phase III study, nivolumab significantly improved disease-free survival compared with placebo in patients with oesophageal or gastro-oesophageal junction cancer who had complete resection and residual pathologic disease after neoadjuvant chemoradiotherapy.</p>	<p>Available in line with national guidance</p>	<p><a href="#">189</a></p>	<p>May 2022</p>
<p>Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2385</p>	<p>In combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).</p> <p>In a phase III study of patients with previously untreated, unresectable MPM, overall survival was significantly longer in the nivolumab plus ipilimumab group compared with standard chemotherapy.</p>	<p>Available in line with national guidance</p>	<p><a href="#">188</a></p>	<p>April 2022</p>
<p>Nivolumab (Opdivo) NSCLC Bristol-Myers Squibb SMC2397</p>	<p>In combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.</p>	<p>Not available as not recommended for use in NHS Scotland</p>	<p><a href="#">188</a></p>	<p>April 2022</p>
<p>Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) SMC2394</p>	<p>In combination with ipilimumab for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer after prior fluoropyrimidine-based combination</p>	<p>Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference</p>	<p><a href="#">188</a></p>	<p>April 2022</p>

	chemotherapy. In a single-arm cohort of a phase II study, nivolumab in combination with ipilimumab was associated with clinically relevant overall response rates in adults with dMMR or MSI-H metastatic colorectal cancer who had received prior fluoropyrimidine-based chemotherapy.	for alternative medicines		
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2362	As monotherapy for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.	Available in line with national guidance	<a href="#">186</a>	Sept 2021
Nivolumab 10mg/ml concentrate for solution for dilution (Opdivo®) SMC2153	In combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by September 2019.	<a href="#">175</a> <a href="#">176</a>	Aug 2019 Oct 2019
Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) SMC2112	As monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection	Available in line with local guidance for prescribing	<a href="#">173</a>	March 2019
Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) SMC No 1285/18	Nivolumab as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy	Not available as not recommended for use in NHS Scotland	<a href="#">167</a>	April 2018
Nivolumab, 10mg/mL concentrate for solution for infusion (Opdivo®) SMC No. (1261/17)	As monotherapy for the treatment of chronic lymphocytic leukaemia (CLL): In the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway	Available in line with national guidance	<a href="#">164</a>	Oct 2017
Nivolumab 10mg/mL concentrate for solution	The treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem	Available in line with national guidance	<a href="#">163</a>	Sep 2017



for infusion (Opdivo®) SMC No (1240/17)	cell transplant (ASCT) and treatment with brentuximab vedotin			
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC 1188/16	As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.	Available in line with national guidance	<a href="#">158</a> <a href="#">162</a>	Dec 2016 Aug 2017
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC 1187/16	In combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults.  SMC restriction: for the first-line treatment of advanced melanoma	Available in line with national guidance	<a href="#">158</a>	Dec 2016
Nivolumab, 10mg/ml, concentrate for solution for infusion (Opdivo®) SMC 1180/16	Treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.	Available in line with national guidance	<a href="#">158</a>	Dec 2016
Nivolumab (Opdivo®)1144/16	Treatment of locally advanced or metastatic squamous non small cell lung cancer after prior chemotherapy in adults.	Available in line with National Guidance	<a href="#">156</a>	Sep 2016
Nivolumab 10mg/mL, concentrate for solution for infusion (Opdivo®) 1120/16	As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Available in line with national guidance	<a href="#">154</a> <a href="#">155</a> <a href="#">156</a>	May 2016 June 2016 Sep 2016
Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) SMC2519	In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression $\geq 1\%$ .	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">194</a>	September 2023
Nomegestrol	Oral contraception	Not recommended	<a href="#">129</a>	Aug/Sept 2013

acetate/estradiol (Zoely®) (898/13)				
Norelgestomic/ethinyloest radiol patch (Evra®)	Female contraception		<a href="#">31</a>	2003
Nusinersen 12mg solution for injection (Spinraza®) SMC No 1318/18	For the treatment of 5q spinal muscular atrophy (SMA).  SMC Restriction: patients with symptomatic type 1 SMA (infantile onset).	Available in line with national guidance	<a href="#">169</a>	July 2018

Updated: 17th January 2024

[Back to top](#)

[Back to homepage](#)